Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]
News [3692]
Articles [22]
Editorials [1]
Conferences [136]
elearning [0]
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
25 Jan 2023
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2023
ASH 2022: Multiple myeloma roundup
Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...
Dr Mark Litzow - Mayo Clinic, Rochester, USA
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )
19 Dec 2022
Breast cancer in elderly patients: a clinicopathological review of a Nigerian...
Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀...
Breast cancer in elderly patients: a clinicopathological review of a Nigerian database ( Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria )
15 Dec 2022
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...
Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )
12 Dec 2022
Treatment decision guided by CTC count may improve long-term outcomes for mBC
Prof Jean-Yves Pierga - Institut Curie, Paris, France
Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )
9 Dec 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation